FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040143310> ?p ?o ?g. }

• W2040143310 endingPage "1259" @default.
• W2040143310 startingPage "1252" @default.
• W2040143310 abstract "Sunitinib at 50 mg/day on the 4-weeks-on-2-weeks-off schedule is the current approved regimen for advanced/metastatic renal cell carcinoma (mRCC). Escudier et al reported that continuous, once-daily dosing with sunitinib 37.5 mg had a manageable safety profile and significant antitumor activity as second-line mRCC therapy. In this prospective, multicenter, phase II study, we evaluated the activity of continuous once-daily dosing with sunitinib 37.5 mg as first-line mRCC treatment.One hundred nineteen treatment-naive patients with measurable mRCC received sunitinib. The primary endpoint was objective response; secondary endpoints included progression-free survival (PFS), safety, pharmacokinetic measurements, exploration of response biomarkers, and patient reported outcomes (PRO).Objective response rate (ORR) was 35.3%; median response duration was 10.4 months; 36% of patients had stable disease ≥12 weeks. Median PFS at 1 year was 9 months, and 1-year survival probability was 67.8%. The most common any-grade treatment-related adverse events (AEs) were diarrhea (50%) and hand-foot syndrome (43%); the most common grade 3-4 treatment-related AEs were hand-foot syndrome (13%), neutropenia (11%), and diarrhea (9%). Steady-state pharmacokinetics were reached within 3 weeks, with no disproportionate accumulation of sunitinib or its active metabolite throughout the study. No significant correlations between trough drug, active metabolite, or soluble protein levels and clinical response were observed. PRO was largely maintained, although fatigue appeared to worsen after treatment started, with improvement over time.Continuous once-daily dosing with sunitinib 37.5 mg was active with a manageable safety profile as first-line mRCC therapy, making this a feasible alternative dosing regimen." @default.
• W2040143310 created "2016-06-24" @default.
• W2040143310 creator A5006624845 @default.
• W2040143310 creator A5011152885 @default.
• W2040143310 creator A5021075431 @default.
• W2040143310 creator A5024676627 @default.
• W2040143310 creator A5027087096 @default.
• W2040143310 creator A5027877389 @default.
• W2040143310 creator A5042341977 @default.
• W2040143310 creator A5051429729 @default.
• W2040143310 creator A5056084189 @default.
• W2040143310 creator A5060759473 @default.
• W2040143310 creator A5063376558 @default.
• W2040143310 creator A5066161983 @default.
• W2040143310 creator A5072075374 @default.
• W2040143310 date "2011-09-06" @default.
• W2040143310 modified "2023-10-18" @default.
• W2040143310 title "Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma" @default.
• W2040143310 cites W1965664963 @default.
• W2040143310 cites W1978083619 @default.
• W2040143310 cites W1989535705 @default.
• W2040143310 cites W1999966467 @default.
• W2040143310 cites W2014075906 @default.
• W2040143310 cites W2038962823 @default.
• W2040143310 cites W2089524549 @default.
• W2040143310 cites W2099088585 @default.
• W2040143310 cites W2100669312 @default.
• W2040143310 cites W2103506609 @default.
• W2040143310 cites W2105677187 @default.
• W2040143310 cites W2118677643 @default.
• W2040143310 cites W2139248078 @default.
• W2040143310 cites W2145046367 @default.
• W2040143310 cites W2149032069 @default.
• W2040143310 cites W2149456801 @default.
• W2040143310 cites W2149613039 @default.
• W2040143310 cites W2150452646 @default.
• W2040143310 cites W2153867442 @default.
• W2040143310 cites W2155012968 @default.
• W2040143310 cites W2156408558 @default.
• W2040143310 cites W2157262448 @default.
• W2040143310 doi "https://doi.org/10.1002/cncr.26440" @default.
• W2040143310 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21898376" @default.
• W2040143310 hasPublicationYear "2011" @default.
• W2040143310 type Work @default.
• W2040143310 sameAs 2040143310 @default.
• W2040143310 citedByCount "82" @default.
• W2040143310 countsByYear W20401433102012 @default.
• W2040143310 countsByYear W20401433102013 @default.
• W2040143310 countsByYear W20401433102014 @default.
• W2040143310 countsByYear W20401433102015 @default.
• W2040143310 countsByYear W20401433102016 @default.
• W2040143310 countsByYear W20401433102017 @default.
• W2040143310 countsByYear W20401433102018 @default.
• W2040143310 countsByYear W20401433102019 @default.
• W2040143310 countsByYear W20401433102020 @default.
• W2040143310 countsByYear W20401433102021 @default.
• W2040143310 countsByYear W20401433102022 @default.
• W2040143310 countsByYear W20401433102023 @default.
• W2040143310 crossrefType "journal-article" @default.
• W2040143310 hasAuthorship W2040143310A5006624845 @default.
• W2040143310 hasAuthorship W2040143310A5011152885 @default.
• W2040143310 hasAuthorship W2040143310A5021075431 @default.
• W2040143310 hasAuthorship W2040143310A5024676627 @default.
• W2040143310 hasAuthorship W2040143310A5027087096 @default.
• W2040143310 hasAuthorship W2040143310A5027877389 @default.
• W2040143310 hasAuthorship W2040143310A5042341977 @default.
• W2040143310 hasAuthorship W2040143310A5051429729 @default.
• W2040143310 hasAuthorship W2040143310A5056084189 @default.
• W2040143310 hasAuthorship W2040143310A5060759473 @default.
• W2040143310 hasAuthorship W2040143310A5063376558 @default.
• W2040143310 hasAuthorship W2040143310A5066161983 @default.
• W2040143310 hasAuthorship W2040143310A5072075374 @default.
• W2040143310 hasBestOaLocation W20401433101 @default.
• W2040143310 hasConcept C112705442 @default.
• W2040143310 hasConcept C126322002 @default.
• W2040143310 hasConcept C143998085 @default.
• W2040143310 hasConcept C197934379 @default.
• W2040143310 hasConcept C203092338 @default.
• W2040143310 hasConcept C2777063308 @default.
• W2040143310 hasConcept C2777288759 @default.
• W2040143310 hasConcept C2777472916 @default.
• W2040143310 hasConcept C2779490328 @default.
• W2040143310 hasConcept C2781413609 @default.
• W2040143310 hasConcept C29730261 @default.
• W2040143310 hasConcept C31760486 @default.
• W2040143310 hasConcept C535046627 @default.
• W2040143310 hasConcept C71924100 @default.
• W2040143310 hasConcept C90924648 @default.
• W2040143310 hasConceptScore W2040143310C112705442 @default.
• W2040143310 hasConceptScore W2040143310C126322002 @default.
• W2040143310 hasConceptScore W2040143310C143998085 @default.
• W2040143310 hasConceptScore W2040143310C197934379 @default.
• W2040143310 hasConceptScore W2040143310C203092338 @default.
• W2040143310 hasConceptScore W2040143310C2777063308 @default.
• W2040143310 hasConceptScore W2040143310C2777288759 @default.
• W2040143310 hasConceptScore W2040143310C2777472916 @default.
• W2040143310 hasConceptScore W2040143310C2779490328 @default.
• W2040143310 hasConceptScore W2040143310C2781413609 @default.

• next